Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
about
The antiangiogenic effects of a vascular endothelial growth factor decoy receptor can be monitored in vivo using contrast-enhanced ultrasound imaging.Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyAntivascular therapy for epithelial ovarian cancer.The VEGF family in cancer and antibody-based strategies for their inhibition.Lymphangiogenesis and lymphatic metastasis in breast cancer.Ovarian cancer development and metastasis.Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models.A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application.Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft modelVascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Emerging treatment options for management of malignant ascites in patients with ovarian cancer.A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors.Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancerMacrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian CancerAntiangiogenic therapy in human gastrointestinal malignancies.Therapeutic options to target angiogenesis in human malignancies.Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.Development of antiangiogenic agents for ovarian cancer.Cancer prevention and therapy through the modulation of the tumor microenvironment.Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications.Epithelial ovarian cancer experimental models.Peritoneal immune system in patients with advance epithelial ovarian cancer.Intraperitoneal delivery of nanoparticles for cancer gene therapy.Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition.Aflibercept--a decoy VEGF receptor.Advances and new perspectives in the treatment of metastatic colon cancer.Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept.Interactions Between Therapeutic Proteins and Small Molecules: The Shared Role of Perpetrators and Victims.Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer
P2860
Q30409780-8F7C17A8-3E97-43E0-83BC-D3B5442D0C04Q30423597-98AF0AE0-5520-46DD-9AD5-78E2AB0F2028Q30424925-5A99CE34-64D6-4228-944F-1DE24C82521DQ30455612-D474F9BB-C2ED-4A6D-B5E0-D7BB2B9C38F5Q33583598-3CABB15E-7DF7-4B4E-A3A0-C767FA887CD1Q33733437-DC2BE802-8FCF-4593-AFCD-278BB121A010Q33940058-95FC439A-F348-4805-B7A9-5718C1EAAA77Q34086819-57EA4084-5CAF-4611-8D2F-1B8AF585456DQ34348270-DA7D4AEA-D567-4FAC-A018-9CDDA6DEDF69Q34557233-3675C635-CA55-4AB3-AE20-31C2C132DA4BQ34694524-1508B164-714A-4CBC-AA55-56EBC2C06ED9Q35013760-2D7FA870-90A3-4115-944E-287A472EC581Q35233993-04F9278E-DF91-4F1A-ADB5-2F753FEBF288Q35538164-5F573A43-208C-4A14-9411-B470784DC800Q35750289-D9B3F699-C872-4645-9968-F5544EFBA8D4Q35938926-DFE5F54F-A182-4728-8ECF-33A2AA076A44Q35954103-A90AFC35-92D9-43C5-BA37-E8B91F3B5873Q36173084-399144C3-4FC8-43D1-B8C4-E3D02878A76CQ36205399-A002F9EF-80DF-4EE0-BA51-B2060B3DB5DEQ36299097-8F6F1A84-2D02-4143-8B9B-0B8E3937D730Q36362871-85A5D9DC-6A11-452B-8B4E-F58CF807E998Q36591067-07BBF77F-ABB1-48B6-AF47-8E8BE9898091Q36634261-5753110F-5613-4FDD-A8C3-B8D23F0B8784Q36971300-DBDF10E7-0696-4662-8317-8AF6DC66F5DCQ37038884-7E7FCDA9-C6A7-41DC-8549-FF2A37D022F5Q37058267-EE8DCC30-5535-4234-9DFD-259B42E49E26Q37375540-E1671BB0-DF81-4481-93CC-1467B5A04ACEQ37454384-86C75FD2-4B2B-477C-B809-41B76ED02BFCQ37708938-6FF46DD7-DCFB-442A-9949-04051279D2FFQ37873925-410340E9-9517-47B9-B496-0E0CC938E158Q38068493-FF8ED4B9-9813-4929-B74F-4C2998864A95Q38172849-EF621155-D440-4BFC-8496-E8DBCDA0FD2CQ38180313-F6FF342B-2D58-45D1-A494-F294930E8D50Q38229589-0DADAE81-A2D1-42B3-B3A0-768D24106747Q38241190-24E641D5-2D03-48CE-AB8E-7B8A85923BABQ39047005-6723F937-8C80-48F3-BD04-45C20DBB53EAQ39396206-48926BCA-0201-4F71-BB77-0D5FC1CA4D77Q40024233-60F6D481-AF0C-4690-B039-A55151352614Q49593669-43E8813E-B906-4BF2-936C-7848099FFE65Q57416431-3B4F270D-0554-4756-9F80-2DD58DF9B23A
P2860
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Vascular endothelial growth fa ...... a human ovarian cancer model.
@en
type
label
Vascular endothelial growth fa ...... a human ovarian cancer model.
@en
prefLabel
Vascular endothelial growth fa ...... a human ovarian cancer model.
@en
P2093
P1476
Vascular endothelial growth fa ...... a human ovarian cancer model.
@en
P2093
Anil K Sood
George D Yancopoulos
Jocelyn Holash
Judith Hofmann
Robert B Jaffe
P304
P356
10.1158/1078-0432.CCR-05-0910
P407
P433
P577
2005-10-01T00:00:00Z